Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis-Reference-Cited by-同舟云学术

Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis

Published:2021-10-16 Issue:11 Volume:41 Page:1011-1020
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Barker Jonathan,Baker Hannah,Nadeem Ayeda,Gu Dong-Ha,Girolomoni Giampiero^ORCID

Funder

Università degli Studi di Verona

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-021-01089-4.pdf

Reference30 articles.

1. National Institute for Health and Care Excellence. Psoriasis: assessment and management [CG153]. https://www.nice.org.uk/guidance/cg153. Accessed 13 Oct 2021.

2. National Institute for Health and Care Excellence. Pathway for psoriasis. https://pathways.nice.org.uk/pathways/psoriasis. Accessed 11 Oct 2021.

3. Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628–37.

4. Fonia A, Jackson K, LeReun C, Grant DM, Barker JNWN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol. 2010;163(4):807–16.

5. British Association of Dermatologists. British Association of Dermatologists’ position Statement on biosimilars. https://www.bad.org.uk/healthcare-professionals/badbir. Accessed 13 Oct 2021.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective;PLOS ONE;2024-09-06

2. Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation;PLOS ONE;2024-08-09

3. [Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate–severe psoriasis with certolizumab pegol;Farmacia Hospitalaria;2023-12

4. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review;Dermatology and Therapy;2023-09-14

5. Acuerdo de riesgo compartido basado en resultados de salud para el tratamiento de psoriasis moderada-grave con certolizumab pegol;Farmacia Hospitalaria;2023-09